Daclizumab for treating relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA441
  • Published: 

This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s advice on daclizumab.